Adlai Nortye (NASDAQ:ANL) Shares Down 8% – Here’s What Happened

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) shares fell 8% during trading on Wednesday. The stock traded as low as $8.51 and last traded at $8.72. Approximately 141,453 shares changed hands during trading, a decline of 60% from the average daily volume of 356,535 shares. The stock had previously closed at $9.48.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ANL shares. Loop Capital set a $49.00 price objective on Adlai Nortye in a research report on Tuesday, September 8th. Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a report on Monday, October 5th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Adlai Nortye in a research report on Tuesday, September 8th. Wall Street Zen lowered Adlai Nortye from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

View Our Latest Analysis on Adlai Nortye

Adlai Nortye Price Performance

The firm’s 50-day moving average is $12.80 and its two-hundred day moving average is $11.70.

Insiders Place Their Bets

In other news, CFO Xiaofeng Ye sold 6,000 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $13.98, for a total transaction of $83,880.00. Following the sale, the chief financial officer directly owned 153,424 shares in the company, valued at approximately $2,144,867.52. This represents a 3.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ping Ji sold 10,000 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total transaction of $159,900.00. Following the completion of the transaction, the director directly owned 121,453 shares of the company’s stock, valued at approximately $1,942,033.47. The trade was a 7.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 26,881 shares of company stock valued at $411,060 over the last three months.

Institutional Investors Weigh In On Adlai Nortye

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Adlai Nortye in the 3rd quarter worth approximately $25,000. ACT Capital Partners L.P. purchased a new stake in Adlai Nortye during the 3rd quarter valued at $430,000. Renaissance Technologies LLC purchased a new stake in Adlai Nortye during the 1st quarter valued at $457,000. Goldman Sachs Group Inc. purchased a new stake in Adlai Nortye during the 3rd quarter valued at $506,000. Finally, State Street Corp bought a new stake in Adlai Nortye in the third quarter worth $579,000. 35.21% of the stock is currently owned by hedge funds and other institutional investors.

About Adlai Nortye

(Get Free Report)

Adlai Nortye is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2004 and headquartered in Hangzhou, China, the company conducts drug research and development for potential use in China and international markets. Its investigational oncology pipeline includes AN2025, a pan-RAF inhibitor; AN0025, an EP4 antagonist; and AN4005, an adenosine A2A/A2B receptor antagonist. These candidates are being studied for their potential to treat solid tumors, including in combination with other cancer therapies.

Recommended Stories

Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.